Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON41215
NL-OMON41215CompletedNot Applicable

AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) - AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)

Chiesi Farmaceutici S.p.A.0 sites104 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
104
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •Asthmatic patient inclusion criteria
  • •1. Male or female patients aged >= 18 and <= 65 years, who have signed an Informed Consent form prior to initiation of any study-related procedure.
  • •2. Clinical diagnosis of asthma for at least 6 months confirmed by a chest physician according to international guidelines (GINA 2012) supported by objective evidence of any of the following at the baseline visit or in the previous 5 years.
  • •a) Positive response to methacholine challenge test [PC20 < 8 mg/mL or PD20 < 0.7 mg for those subjects not using inhaled corticosteroids (ICS), and PC20 < 16 mg/mL or PD20 < 1.4 mg for subjects using ICS]
  • •b) Positive response to a reversibility test, defined as ΔFEV1 >= 12% and >= 200 mL over baseline FEV1, within 30 minutes after administration of 400 µg of salbutamol pMDI administered with or without Spacer
  • •c) Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the two, × 100) > 20%, measured over a follow-up period of 7 days
  • •d) Documented response (defined as ΔFEV1 >= 12% and >= 200 mL) after a cycle (e.g., 4 weeks) of regular maintenance anti-asthma treatment.
  • •3. Patients with stable asthma, on any previous regular asthma treatment (*rescue* β2-agonists alone included) at a stable dose, for at least 8 weeks prior to baseline visit.
  • •4. Current smoker, ex-smoker (since the past 12 months) or lifelong non-smoker (total lifetime smoking history < 10 packyears defined as [(number of cigarettes smoked per day) x(number of years of smoking)] / 20).
  • •Healthy subject inclusion criteria
  • •1. Male or female patients aged >= 18 and <= 65 years, who have signed the Informed Consent form prior to initiation of any study-related procedure.
  • •2. No clinical history of asthma or COPD (no respiratory symptoms compatible to asthma or COPD in the past 2 years).
  • •3. Current smoker, ex-smoker (since the past 12 months) or lifelong non-smoker (total lifetime smoking history < 10 packyears).
  • •4. Normal spirometry: baseline FEV1 >= 80% of the predicted normal value, FEV1/FVC > LLN (lower limit of normal).
  • •5. Normal airways responsiveness: PC20 >= 16 mg/mL, PD20 >= 1.4 mg.

Exclusion Criteria

  • •Asthmatic patient exclusion criteria
  • •1. Cigarette smoking > 10 packyears defined as [(number of cigarettes smoked per day) x (number of years of smoking)] / 20.
  • •2. diagnosis of COPD confirmed by a chest physician.
  • •3. Asthma exacerbation in the 8 weeks prior to baseline visit (defined as a significant deterioration of asthma and signalled by any or more of the following: need for a systemic corticosteroid course (>= 3 days); hospitalisation for asthma; emergency room attendance for asthma).
  • •4. Clinical or functional uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that might, in the judgment of the investigator, compromise the results or interpretation of the study.
  • •5. Pregnant or lactating women (a urine pregnancy test will be performed).
  • •6. Participation in an interventional clinical trial with intake of the last dose of any investigational drug <12 weeks preceding baseline visit (last dose < 5 half-lives prior to baseline visit for biologics).
  • •7. Inability to comply with study procedures.
  • •8. Alcohol or drug abuse.;Healthy subject exclusion criteria
  • •1. Cigarette smoking history > 10 packyears defined as [(number of cigarettes smoked per day) x (number of years of smoking)] / 20.
  • •2. Diagnosed upper and/or lower respiratory disease(s).
  • •3. Clinical or functional uncontrolled haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that might, in the judgment of the investigator, compromise the results or interpretation of the study.
  • •4. Pregnant or lactating women (a urine pregnancy test will be performed).
  • •5. Participation in an interventional clinical trial with intake of the last dose of any investigational drug <12 weeks preceding baseline visit (last dose < 5 half-lives prior to baseline visit for biologics).
  • •6. Inability to comply with study procedures.
  • •7. Alcohol or drug abuse.

Investigators

Similar Trials

Completed
Not Applicable
AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)Asthma
NCT02123667Chiesi Farmaceutici S.p.A.872
Completed
Not Applicable
Study on mortality of asthmatic patients with airflow obstruction based on cohort of air pollution-related respiratory diseases in Omuta cityasthma
JPRN-UMIN000031509Kurume University697
Completed
Phase 3
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)Asthma
NCT00163345AstraZeneca20
Recruiting
Phase 1
A study to assess the effect allergic rhinitis in a non asthmatic individual on the lung functions
CTRI/2019/01/016940il
Completed
Not Applicable
Assessment of inflammatory characteristics and cell function with changes in asthma controlAsthma
ACTRN12617001356358Centre for Public Health Research, Massey University.45
AssessmenT of smalL Airways involvemeNT In... | Clinical Trial